NASDAQ:SQNM Sequenom (SQNM) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free SQNM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$2.39▼$2.3950-Day Range N/A52-Week Range$0.82▼$2.53VolumeN/AAverage Volume1.27 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sequenom alerts: Email Address Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Sequenom Stock (NASDAQ:SQNM)Sequenom, Inc. is a life sciences company. The Company serves patients and physicians by providing early patient management information. The Company operates through Sequenom Laboratories segment. It conducts its business as a molecular diagnostics clinical laboratory located in San Diego, California and Raleigh-Durham, North Carolina. Its testing focus is on prenatal health that includes molecular-based laboratory developed tests (LDTs). The Company's diagnostic services are provided through its subsidiary, Sequenom Center for Molecular Medicine LLC (SCMM), doing business as Sequenom Laboratories. Sequenom Laboratories develops and validates its tests to be used as a testing service to physicians. Sequenom Laboratories is focused on developing and offering a menu of tests for prenatal continuum of care. The Sequenom Laboratories' test offerings in the prenatal market include MaterniT21 PLUS LDT, HerediT CF test, SensiGene RhD test, VisibiliT test and Test Send-out Agreements.Read More Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. SQNM Stock News HeadlinesSeptember 9, 2023 | thestreet.com5 Biotech Stocks Under $10 Set to SoarJuly 23, 2023 | thestreet.comSequenom Fallout Hits Hedge FundsApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.May 18, 2023 | reuters.comLatest Markets NewsFebruary 27, 2023 | thestreet.comSequenom Still Very Good, Just No Longer PerfectJanuary 7, 2023 | thestreet.comPast Sequenom Exec Charged with Lying by SECOctober 19, 2022 | streetinsider.comJUNO DIAGNOSTICS STRENGTHENS THE ORGANIZATION WITH APPOINTMENT OF GINA GRAYUM TO COMMERCIAL LEADERSHIP TEAM - StreetInsider.comOctober 18, 2022 | prnewswire.comJUNO DIAGNOSTICS STRENGTHENS THE ORGANIZATION WITH APPOINTMENT OF GINA GRAYUM TO COMMERCIAL LEADERSHIP TEAM - PR NewswireApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… October 12, 2022 | globenewswire.comPrenatal and Newborn Genetic Testing Market to hit US$ 12.70 Billion by 2030 | Exclusive Report by Growth Plus Reports - GlobeNewswireOctober 10, 2022 | globenewswire.comViral Antigens Market to Reach US$ 0.292 billion by 2030 Size, Shares, Forecasts, and Trends Analysis Report with COVID-19 Impact by Growth Plus Reports - GlobeNewswireSeptember 23, 2022 | seekingalpha.comInvitae: Losses & Debt Suggest Bearish Sentiment Is Deserved - Seeking AlphaSeptember 19, 2022 | businesswire.comWorld Non-Invasive Prenatal Testing (NIPT) Pipeline Market Report 2022: Comparative Analysis at Various Stages of Development and Information on Clinical Trials in Progress - ResearchAndMarkets.com - Business WireSeptember 7, 2022 | businesswire.comAnsa Bio Appoints Lorna Neilson, Ph.D. as Chief Business Officer - Business WireJuly 1, 2022 | globenewswire.comThe Worldwide Carrier Screening Industry is Expected to Reach $3.64 Billion by 2030 - GlobeNewswireJune 29, 2022 | uk.finance.yahoo.comThe Worldwide Carrier Screening Industry is Expected to Reach $3.64 Billion by 2030 - Yahoo Finance UKJune 23, 2022 | prnewswire.comNew Analysis from Global Industry Analysts Reveals Steady Growth for Genotyping, with the Market to Reach $39.9 Billion Worldwide by 2026 - PR NewswireJune 23, 2022 | finance.yahoo.comNew Analysis from Global Industry Analysts Reveals Steady Growth for Genotyping, with the Market to Reach $39.9 Billion Worldwide by 2026 - Yahoo FinanceJune 5, 2022 | seekingalpha.comLaboratory Corp: 15% Reward Asymmetry Under-Reflected, Seeking Exit At $280 Per Share - Seeking AlphaMay 31, 2022 | finance.yahoo.comAadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications - Yahoo FinanceMay 13, 2022 | law360.comFed. Circ. Says LabCorp Missed Chance To Move Patent Row - Law360April 6, 2022 | prnewswire.comIDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors - PR NewswireMarch 9, 2022 | businesswire.comGlobal Non-invasive Prenatal Testing Market Report 2022: By Type, End User, Instruments, Consumables and Application - ResearchAndMarkets.com - Business WireFebruary 7, 2022 | finance.yahoo.comAmbrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee - Yahoo FinanceFebruary 7, 2022 | businesswire.comAmbrx Biopharma Inc. Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee - Business WireFebruary 7, 2022 | streetinsider.comAmbrx Biopharma (AMAM) Appoints Paul Maier to Board of Directors and as Chair of the Audit Committee - StreetInsider.comJanuary 26, 2022 | globenewswire.comGlobal Genotyping Assay Market to Reach Over $40.0 Billion by 2028 - GlobeNewswireSee More Headlines Receive SQNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sequenom and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:SQNM CUSIP81733740 CIK1076481 Webwww.sequenom.com Phone+1-858-2029000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report SQNM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Sequenom own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sequenom investors own include Arch Resources (ARCH), PotlatchDeltic (PCH), Illumina (ILMN), LinnCo (LNCOQ), Conatus Pharmaceuticals (CNAT), DryShips (DRYS), La Jolla Pharmaceutical (LJPC), NovoCure (NVCR), Acer Therapeutics (ACER) and Aeterna Zentaris (AEZS). This page (NASDAQ:SQNM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sequenom Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
